762
Views
10
CrossRef citations to date
0
Altmetric
Drug Evaluation

Lurasidone in the treatment of schizophrenia: a critical evaluation

, MD, , MD, , MD & , MD

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Awais Aftab & Keming Gao. (2017) The preclinical discovery and development of brexpiprazole for the treatment of major depressive disorder. Expert Opinion on Drug Discovery 12:10, pages 1067-1081.
Read now
Lynn McClellan, Kelli C. Dominick, Ernest V. Pedapati, Logan K. Wink & Craig A. Erickson. (2017) Lurasidone for the treatment of irritability and anger in autism spectrum disorders. Expert Opinion on Investigational Drugs 26:8, pages 985-989.
Read now

Articles from other publishers (8)

Martin Tarzian, Majd Soudan, Muhammed Alhajji, Mariana Ndrio & Adegbenro O Fakoya. (2023) Lurasidone for Treating Schizophrenia and Bipolar Depression: A Review of Its Efficacy. Cureus.
Crossref
Jolanta Orzelska-Górka, Joanna Mikulska, Anna Wiszniewska & Grażyna Biała. (2022) New Atypical Antipsychotics in the Treatment of Schizophrenia and Depression. International Journal of Molecular Sciences 23:18, pages 10624.
Crossref
Donald E. Greydanus, Dilip R. Patel & Dustin C. Rowland. 2022. Comprehensive Pharmacology. Comprehensive Pharmacology 396 434 .
Samskruthi Madireddy & Sahithi Madireddy. (2020) Regulation of Reactive Oxygen Species-Mediated Damage in the Pathogenesis of Schizophrenia. Brain Sciences 10:10, pages 742.
Crossref
Harika Modugula & Anoop Kumar. (2020) Risk Analysis of Lurasidone in Patients with Schizophrenia and Bipolar Depression. CNS & Neurological Disorders - Drug Targets 19:2, pages 109-114.
Crossref
Afzal Javed, Holger Arthur, Logos Curtis, Lars Hansen & Sofia Pappa. (2019) Practical Guidance on the Use of Lurasidone for the Treatment of Adults with Schizophrenia. Neurology and Therapy 8:2, pages 215-230.
Crossref
Jiang Li, Akane Yoshikawa, Mark D. Brennan, Timothy L. Ramsey & Herbert Y. Meltzer. (2018) Genetic predictors of antipsychotic response to lurasidone identified in a genome wide association study and by schizophrenia risk genes. Schizophrenia Research 192, pages 194-204.
Crossref
Mei Huang, Sunoh Kwon, Wenqi He & Herbert Y. Meltzer. (2017) Neurochemical arguments for the use of dopamine D 4 receptor stimulation to improve cognitive impairment associated with schizophrenia. Pharmacology Biochemistry and Behavior 157, pages 16-23.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.